Microwave ablation for treating relapsed Graves' disease
A Prospective Evaluation of Microwave Ablation (MWA) in the Treatment of Relapsed Graves' Disease
This study is testing if microwave ablation can help adults with relapsed Graves' disease feel better when other treatments haven't worked.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 25 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | The University of Hong Kong Academic / other |
| Locations | 1 site (Hong Kong) |
| Trial ID | NCT06506149 on ClinicalTrials.gov |
What this trial studies
This study evaluates the effectiveness of microwave ablation (MWA) as a treatment for patients with relapsed Graves' disease who have not responded adequately to anti-thyroid drugs. The approach aims to provide a minimally invasive alternative to conventional treatments like radioiodine and surgery, which may have significant side effects or complications. By using MWA, the study seeks to induce remission in patients while minimizing the risks associated with more invasive procedures. The trial will include patients over 18 years old who have experienced a relapse of Graves' disease after at least 18 months of treatment.
Who should consider this trial
Good fit: Ideal candidates are adults over 18 with relapsed Graves' disease despite adequate treatment with anti-thyroid drugs for 18 months or more.
Not a fit: Patients who prefer surgery or have severe Graves' ophthalmopathy or other contraindications will not benefit from this study.
Why it matters
Potential benefit: If successful, this treatment could offer a safer and more effective option for patients with relapsed Graves' disease.
How similar studies have performed: While microwave ablation is a novel approach for this specific condition, similar minimally invasive techniques have shown promise in other areas of treatment.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * (a) age older than 18 years, * (b) relapsed Graves' disease despite an adequate ATD treatment for 18 months or more * (c) absence of vocal cord immobility Exclusion Criteria: * (a) patients who prefer or are indicated for surgery, * (b) presence of head and/or neck disease preventing hyperextension of the neck, * (c) history of thyroid cancer or other malignant tumours in the neck region, * (d) history of neck irradiation, * (e) severe Graves' ophthalmopathy, * (f) large compressive goitre, * (g) pregnancy or lactation, and * (h) any contraindication to intravenous sedation.
Where this trial is running
Hong Kong
- Queen Mary Hospital — Hong Kong, Hong Kong (Recruiting)
Study contacts
- Study coordinator: Yan Luk, MBBS
- Email: floralukyan@gmail.com
- Phone: +852 2255 4232
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.